Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Items 101–200 of 729

Immunotherapy for colorectal cancer
Yu, B., Kang, J., Lei, H., Li, Z., Yang, H. C., & Zhang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433315 · Cited by 39
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
Hecht, J. R., Park, Y. S., Tabernero, J. M., Lee, M. A., Lee, S. H., Manrique, A. C. V., den Eynde, M. V., Fontana, E., Fakih, M., Asghari, G., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02025-2 · Cited by 42
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 40
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity
Akai, M., Noma, K., Kato, T., Nishimura, S., Matsumoto, H., Kawasaki, K., Kunitomo, T., Kobayashi, T., Nishiwaki, N., Kashima, H., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02639-1 · Cited by 35
MSI colorectal cancer, all you need to know
Flecchia, C., Zaanan, A., Lahlou, W., Basile, D., Broudin, C., Gallois, C., Pilla, L., Karoui, M., Manceau, G., & Taı̈eb, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101983 · Cited by 40
Targeting KRASG12C in colorectal cancer: the beginning of a new era
Ciardiello, D., Maiorano, B. A., & Martinelli, E. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100745 · Cited by 38
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
Español‐Rego, M., Fernández-Martos, C., Élez, E., Foguet, C., Pedrosa, L., Rodríguez, N., Ruiz‐Casado, A., Pineda, E., Cid, J., Cabezón, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03283-5 · Cited by 34
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Kelly, R. J., Bever, K. M., Chao, J., Ciombor, K. K., Eng, C., Fakih, M., Goyal, L., Hubbard, J. M., Iyer, R. V., Kemberling, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006658 · Cited by 36
A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice
Liu, Y., Xie, Y., Chen, Y., Duan, J., Bao, C., Wang, J., Feng, H., Wang, M., Ren, Y., Li, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57965-6 · Cited by 35
Predictors of response to immunotherapy in colorectal cancer
González‐Montero, J., Rojas, C. I., & Burotto, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae152 · Cited by 36
Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer
Chen, Q., Shen, M., Yan, M., Han, X., Mu, S., Li, Y., Luo, L., Wang, Y., Li, S., Li, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05518-8 · Cited by 34
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer
Fan, W., Su, F., Zhang, Y., Zhang, X., Du, Y., Gao, Y., Li, W., Hu, W., & Zhao, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00640-7 · Cited by 35
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 32
Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future
Şahin, İ. H., Zhang, J. Y., Saridogan, T., Gorantla, V. C., Rhree, J., Malhotra, M. K., Thomas, R. A., Hsu, D. J., & Saeed, A. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00762 · Cited by 32
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model
Morehead, L. C., Garg, S., Wallis, K., Simões, C., Siegel, E. R., Tackett, A. J., & Miousse, I. R. (2023) · Cancers · doi:10.3390/cancers15184467 · Cited by 32
Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation
Zhong, Y., Xu, J., Zhou, R., Tang, L., Ding, S., Ren, Z., Song, N., Hu, B., Yang, H., Sun, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02329 · Cited by 32
Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
Hamid, M. A., Pammer, L. M., Lentner, T., Doleschal, B., Gruber, R., Kocher, F., Gasser, E., Jöbstl, A., Seeber, A., & Amann, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01583-w · Cited by 34
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
Ree, A. H., Benth, J. Š., Hamre, H. M., Kersten, C., Hofsli, E., Guren, M. G., Sørbye, H., Johansen, C., Negård, A., Bjørnetrø, T., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02696-6 · Cited by 33
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
Song, D., Hou, S., Ma, N., Yan, B., & Gao, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485303 · Cited by 33
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
Mazzoli, G., Cohen, R., Lonardi, S., Corti, F., Élez, E., Fakih, M., Jayachandran, P., Colle, R., Shah, A. T., Salati, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.044 · Cited by 32
Self-citation
Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 34
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors
Amodio, V., Vitiello, P. P., Bardelli, A., & Germano, G. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02848-8 · Cited by 33
CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
Ghorbaninezhad, F., Masoumi, J., Bakhshivand, M., Baghbanzadeh, A., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Jafarlou, M., Brunetti, O., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931316 · Cited by 31
Chondroitin Sulfate‐Modified Hydroxyapatite for Caspase‐1 Activated Induced Pyroptosis through Ca Overload/ER Stress/STING/IRF3 Pathway in Colorectal Cancer
Chen, Q., Peng, B., Lin, L., Chen, J., Jiang, Z., Luo, Y., Huang, L., Li, J., Peng, Y., Wu, J., et al. (2024) · Small · doi:10.1002/smll.202403201 · Cited by 29
The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review
Schonfeld, E., Choi, J. H., Tran, A., Kim, L. H., & Lim, M. K. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae174 · Cited by 29
Therapeutic targeting of mismatch repair-deficient cancers
Johannet, P. M., Rousseau, B., Aghajanian, C. A., Foote, M. B., & Diaz, L. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01054-6 · Cited by 35
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
Wang, F., Chen, G., Qiu, M., Ma, J., Mo, X., Liu, H., Li, Y., Ding, P., Wan, X., Hu, Y., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.004 · Cited by 30
Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xu, X., Ai, L., Hu, K., Liang, L., Lv, M., Wang, Y., Cui, Y., Li, W., Li, Q., Yu, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51536-x · Cited by 30
Colorectal cancer cell-derived exosomal miRNA-372-5p induces immune escape from colorectal cancer via PTEN/AKT/NF-κB/PD-L1 pathway
Wu, Y., Xiao, Y., Ding, Y., Ran, R., Wei, K., Tao, S., Mao, H., Wang, J., Pang, S., Shi, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113261 · Cited by 28
Recent advances and challenges in colorectal cancer: From molecular research to treatment
Qi, G., Zhao, R., Gao, C., Ma, Z., Wang, S., & Xu, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i21.106964 · Cited by 40
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Current status and prospect of immunotherapy for colorectal cancer
Yang, W., Zheng, H., Lv, W., & Zhu, Y. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04553-z · Cited by 28
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Taïeb, J., Sullo, F. G., Lecanu, A., Bourreau, C., Barbier, E., Gandini, A., Bez, J., Mulot, C., Fiore, F. D., El-Hajbi, F., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1646 · Cited by 30
Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?
Olguín, J. E., Mendoza-Rodríguez, M., Sánchez-Barrera, C. Á., & Terrazas, L. I. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i2.251 · Cited by 30
Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis
Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., & Fenix, K. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006764 · Cited by 26
Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer
Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 29
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer
Martinelli, E., Arnold, D., Cervantes, A. M. R., Stintzing, S., Cutsem, E. V., Tabernero, J. M., Taı̈eb, J., Wasan, H. S., & Ciardiello, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102541 · Cited by 25
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges
Li, C. M. Y., Li, R., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., Tomita, Y., & Fenix, K. A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102665 · Cited by 25
Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 24
Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling
Rathore, M. G., Curry, K., Huang, W., Wright, M., Martin, D., Baek, J. Y., Taylor, D. J., Miyagi, M., Tang, W., Feng, H., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.10.004 · Cited by 24
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 27
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
Shimozaki, K., Nakayama, I., Hirota, T., & Yamaguchi, K. (2023) · Cells · doi:10.3390/cells12071049 · Cited by 25
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
Noori, M., Jafari‐Raddani, F., Davoodi‐Moghaddam, Z., Delshad, M., Safiri, S., & Bashash, D. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03183-3 · Cited by 26
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
Randon, G., Aoki, Y., Cohen, R., Provenzano, L., Nasca, V., Klempner, S. J., Maron, S. B., Cerantola, R., Chao, J., Fornaro, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007104 · Cited by 23
Self-citation
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
Vitiello, P. P., Rousseau, B., Chilà, R., Battuello, P., Amodio, V., Battaglieri, V., Grasso, G., Scardellato, S., Anselmo, A., Clemente, F., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.014 · Cited by 26
Target identification and assessment in the era of AI
Pun, F. W., Podolskiy, D. I., Izumchenko, E., Mortlock, A. A., Oprea, T. I., Scheibye‐Knudsen, M., Fortney, K., Morgen, E. K., Ren, F., & Zhavoronkov, A. A. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01412-8 · Cited by 31
Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Tintelnot, J., Ristow, I., Sauer, M., Simnica, D., Schultheiß, C., Scholz, R., Goekkurt, E., von Wenserski, L., Willscher, E., Paschold, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.993611 · Cited by 23
Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities
Zhang, W., Jin, C., Liu, S., Wan, X., Li, Y., Liu, J., Duan, Z., Ma, J., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757513 · Cited by 22
Multimodal Management of Colorectal Liver Metastases: State of the Art
Filoni, E., Musci, V., Rito, A. D., Inchingolo, R., Memeo, R., & Mannavola, F. (2024) · Oncology Reviews · doi:10.3389/or.2023.11799 · Cited by 22
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 27
Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials
Germani, M. M., & Moretto, R. (2021) · Cancers · doi:10.3390/cancers14010052 · Cited by 21
CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway
Xu, G., Zhao, L., Hua, Q., Wang, L., Liu, H., Lin, Z., Jin, M., Wang, J., Zhou, P., Yang, K., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05644-z · Cited by 22
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Ciurej, A., Lewis, E. C., Gupte, A., & Al‐Antary, E. T. (2023) · Vaccines · doi:10.3390/vaccines11121843 · Cited by 24
Curcumin/L‐OHP co‐loaded HAP for cGAS‐STING pathway activation to enhance the natural immune response in colorectal cancer
Xiao, Y., Guo, G., Wang, H., Peng, B., Lin, Y., Qu, G., Li, B., Jiang, Z., Zhang, F., Wu, J., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10610 · Cited by 20
PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1
Yuan, M., Zhang, C., Chen, S., Ye, S., Liu, H., Ke, H., Huang, J., Liang, G., Yu, R., Hu, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217007 · Cited by 22
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer
Liu, C., Qifeng, J., & Shaolei, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01117-7 · Cited by 22
From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer
Ding, X., Huang, H., Zhang, F., & Jiang, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01282-5 · Cited by 22
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
Ciardiello, D., Mauri, G., Bianchi, A. S., Siena, S., Zampino, M. G., Fazio, N., & Cervantes, A. M. R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102683 · Cited by 23
Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Loree, J. M., Titmuss, E., Topham, J. T., Kennecke, H. F., Feilotter, H. E., Virk, S., Lee, Y. S., Banks, K. C., Quinn, K., Karsan, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0268 · Cited by 21
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 25
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
Wang, Z., Peng, J., Liang, X., Cheng, Y., Deng, Y., Chen, K., Zhang, M., Zhang, J., Wang, W., Cao, B., et al. (2024) · Med · doi:10.1016/j.medj.2024.05.009 · Cited by 22
Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities
Andac-Aktas, A. B., & Calibasi‐Kocal, G. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1687556 · Cited by 25
The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer
Liu, J., Li, J., Luo, F., Wu, S., Li, B., & Liu, K. (2023) · Current Oncology · doi:10.3390/curroncol30110699 · Cited by 22
NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
Raunkilde, L., Hansen, T. F., Andersen, R. F., Havelund, B. M., Thomsen, C. B., & Jensen, L. H. (2022) · Cancers · doi:10.3390/cancers14184459 · Cited by 20
Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review)
Wang, C., Zhang, H., Liu, Y., Wang, Y., Hu, H., & Wang, G. (2023) · Oncology Letters · doi:10.3892/ol.2023.13816 · Cited by 22
The current status and prospect of immunotherapy in colorectal cancer
Shu, Y., & Zheng, S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03235-0 · Cited by 21
Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
Saberzadeh-Ardestani, B., Graham, R. P., McMahon, S., Ahanonu, E., Shi, Q., Williams, C., Hubbard, A., Zhang, W., Murányi, A., Yan, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1109 · Cited by 20
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer
Li, H., Zheng, N., Guo, A., Tang, W., Li, M., Cao, Y., Ma, X., Cao, H., Ma, Y., Wang, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06469-0 · Cited by 22
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations
Khushman, M. M., Toboni, M. D., Xiu, J., Manne, U., Farrell, A. P., Lou, E., Shields, A. F., Philip, P. A., Salem, M. E., Abraham, J. P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3004 · Cited by 20
Self-citation
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions
Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 22
Nanoparticle-based Traditional Chinese Medicine for Immunotherapy in Gastrointestinal Tumors
Peng, L.-J., Liang, Y., Zhang, Q., Guo, X.-N., Gao, Z.-X., & Cui, D. (2025) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2025.9290115 · Cited by 16
The High Expression of SLC7A11 and GPX4 are Significantly Correlated with β-Catenin in Colorectal Cancer
Ou, Y., Wu, N., Shu, L., Zhao, Y., Bao, Y., & Wu, Q. (2024) · Cancer Management and Research · doi:10.2147/cmar.s483526 · Cited by 23
New insight in immunotherapy and combine therapy in colorectal cancer
Ji, K., Jia, H., Liu, Z., Yu, G., Wen, R., Zhang, T., Peng, Z., Man, W., Tian, Y., Wang, C., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1453630 · Cited by 22
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
Dent, J., Jorge, M., Sobrevilla, N., Uldrick, T. S., Adoubi, I., Bajpai, J., Burotto, M., Bulhan, H., Dosunmu, G. T., Ekpo, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011258 · Cited by 24
Consensus Molecular Subtypes (CMS) Classification: a progress towards Subtype-Driven treatments in colorectal cancer
Kantha, A., Das, D., Pai, E., Kumar, T., & Pandey, M. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04117-1 · Cited by 19
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 20
Self-citation
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Shapira‐Frommer, R., Niu, J., Perets, R., Peters, S., Shouse, G., Lugowska, I. A., Garassino, M. C., Sands, J. M., Keenan, T. E., Zhao, B., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2343272 · Cited by 19
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies
Nie, S.-C., Jing, Y., Lu, L., Ren, S.-S., Ji, G., & Xu, H.-C. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1690 · Cited by 22
Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers
Wang, Z., Cheng, S., Yao, Y., Liu, S., Liu, Z., Liu, N., Jin, Y., Zhang, Y., Yin, F., Han, G., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03764-9 · Cited by 18
Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials
Hou, J., Xie, R., Zhang, Z., Liu, Q., Xiang, Q., & Cui, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163971 · Cited by 20
Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
Li, J., & Xu, X. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s408349 · Cited by 18
Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
Christenson, E. S., Tsai, H., Le, D. T., Jaffee, E. M., Dudley, J. C., Xian, R. R., Gocke, C. D., Eshleman, J. R., & Lin, M.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193259 · Cited by 19
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
Wesevich, A., Goldstein, D. A., Paydary, K., Peer, C. J., Figg, W. D., & Ratain, M. J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02367-y · Cited by 18
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 19
Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance
Duta-Ion, S. G., Juganaru, I. R., Hotinceanu, I. A., Dan, A., Burtavel, L. M., Coman, M. C., Focșa, I. O., Zaruha, A.-G., Codreanu, P. C., Bohîlțea, L. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312507 · Cited by 23
Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer
Lin, Y., Yu, X., Liu, S., Hong, L., Shao, L., & Wu, J. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01369-8 · Cited by 17
Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy
Yang, Y., Meng, W., & Wang, Z. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2804069 · Cited by 17
A novel disulfidptosis and glycolysis related risk score signature for prediction of prognosis and ICI therapeutic responsiveness in colorectal cancer
Li, J., Yang, C., & Zheng, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-40381-5 · Cited by 17
KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer
André, T., Pietrantonio, F., Avallone, A., Gümüş, M., Wyrwicz, L. S., Kim, J. G., Yalçın, Ş., Kwiatkowski, M., Lonardi, S., Żołnierek, J., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1105 · Cited by 20
Self-citation
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
Simmons, K., Thomas, J. V., Ludford, K. T., Willis, J. A., Higbie, V. S., Raghav, K. P. S., Johnson, B., Dasari, A. N., Kee, B. K., Parseghian, C. M., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0340 · Cited by 17
Self-citation
Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series
Nádorvári, M. L., Kenessey, I., Kiss, A., Barbai, T., Kulka, J., Rásó, E., & Tı́már, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04960-y · Cited by 17
Potential role of the intratumoral microbiota in colorectal cancer immunotherapy
Fan, S., Zhang, W., Zhou, L., Wang, D., & Tang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112537 · Cited by 16
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Monette, A., Warren, S., Barrett, J. C., Garnett‐Benson, C., Schalper, K. A., Taube, J. M., Topp, B. G., & Snyder, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009427 · Cited by 17
Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer
Luo, M. (2024) · American Journal of Cancer Research · doi:10.62347/myza2640 · Cited by 19
An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer
Bhattacharya, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103916 · Cited by 17
Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review
Patruni, S., Fayyaz, F., Bien, J. Y., Phillip, T. W., & King, D. A. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00226 · Cited by 18
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 18

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks